 |
7, 2, 149–153 (2006)
doi:10.1038/sj.embor.7400627
Figures and Tables
cGMP signalling: from bench to bedside
Conference on cGMP Generators, Effectors and Therapeutic Implications
Robert Feil & Barbara Kemp-Harper
| |
| | |
| |
|
| | |
| | Figures | |
| |
|
|
Figure 1
Current concepts of cGMP signalling. cGMP generators (green) and effectors (red), as well as some downstream pathways and cellular functions (grey boxes) that are involved in the effects of endogenous cGMP and/or cGMP-elevating drugs (blue), are shown. The lower part shows some current (blue) as well as potential future (black) indications for drugs that modulate cGMP levels or cGMP effector pathways. BNP, B-type natriuretic peptide; cGKs, cGMP-dependent protein kinases; IRAG, IP3 receptor-associated cGKI substrate; PDEs, phosphodiesterases; pGC, particulate guanylyl cyclase; sGC, soluble guanylyl cyclase; VASP, vasodilator-stimulated phosphoprotein. See text for details.
|
|
|
| | |
|
